The pandemic of coronavirus 2 (severe acute respiratory syndrome (SARSCoV-2) has significantly changed lives around the world. Musculoskeletal symptoms can develop with SARS-CoV-2 as with other respiratory infections. Viral infections can be cause of arthritis, but the spectrum of symptoms can be quite wide, from arthralgia to chronic arthritis. Coronaviruses can be usually cause of arthralgia and myalgia rather than clinical arthritis. However, a syndrome of dysregulation and systemic overactivation of the immune system, described as a cytokine storm or hyperinflammatory syndrome, can developduring the course of COVID-19. As a result, coagulation and inflammation can significantly affect the progression of the disease and possibly lead to damageof the musculoskeletal system.The aim of the publication is to raise the awareness of rheumatologists and general practitioners, we offer a clinical case of the development of a musculoskeletal system lesion in a patient with COVID-19 and the successful treatment of this condition in this patient.Patients and methods. The article presents a clinical case of patient Z., who was diagnosed with joint lesions on the background of coronavirus infection.The patient was hospitalized in the rheumatology department of the Communal Non-profit Enterprise of the Kharkov Regional Council «Kharkiv RegionalHospital».Results and discussion. The patient underwent a full range of clinical and diagnostic studies and was prescribed systemic therapy with corticosteroids,supportive, as well as antibiotic therapy. The decrease of joint damage symptoms was noted during therapy. Subsequent observation was indicatedan improvement in the patient’s condition after the end of treatment in hospital.Conclusions. Our own experience in the treatment and management of the patient with a lesion of the musculoskeletal system against the background of coronavirus infection presens in the article. The data on clinical cases that were accompanied by joint damage against the background of COVID-19 or occurred some time after a viral infection were presented. Important practical clinical issues related to the diagnosis and management of patients withatypical manifestations of the disease are considered.

The relevance of the article due to the need for the legal regulation of relations regarding the use of cloud computing that have already involved in the most important areas of public life. Currently (along with the undeniable benefits), there are many problems caused by the use of cloud technologies. The current legislation needs to be modified to create a regulatory platform, remedies, and factors to prevent or prevent illegal activity. The authors of this article have used various methods of scientific research, namely the analysis, synthesis, analogy, deduction, induction, formal-legal, comparative-legal, interpretation of law, etc. The study shows that there is currently no legal regulation in Ukraine on the use of cloud technology. Today, it is possible to distinguish several ways of legal regulation of relations on the use of cloud technologies: 1) legal regulation of these relations can be done using already existing regulatory acts; 2) amend the existing legal framework (adaptation of stable legal norms to the new information reality); 3) to create new legal acts on the regulation of exclusive relations related to the use of cloud technologies, taking into account their specifics.

The work is devoted to identifying the main problems of legal regulation of innovations in the medical field and developing the best options for solving them in the context of the Covid-19 pandemic. Thus, the research methodology is based on general and special scientific methods, in particular: formal legal, historical and legal, comparative analysis, and modeling. So, the procedure and issues to be considered are as follows. In the introduction, we will briefly highlight the origins of intellectual property rights issues in the medical field and the overall state of the pharmaceutical industry. In the first subsection of the third section, we will consider the positions of the main players in the pharmaceutical industry and the contradictions between them. In the second subsection, we will highlight the international obligations under TRIPS. In the third subsection, we will consider the consequences of their direct violation. In the fourth subsection, the impact of Covid-19 and the methods of legal regulation of medical innovations and patents under the TRIPS agreement will be discussed. In the fifth subsection, we will propose a way out and a compromise according to the Indian scenario. As a result of the study, contradictions were identified in the aspect of maintaining the balance of private and public interests between states and international pharmaceutical companies in the context of a pandemic and proposed ways to resolve them within the existing legal methods under the TRIPS agreement to achieve an acceptable compromise.